ADXSHER-2 is under clinical development by OS Therapies and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ADXSHER-2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADXS-HER2 (OST-HER2) is under development for the treatment of pediatric osteosarcoma. It is a HER-2/neu vaccine targets internal and external sites on the HER-2 antigen associated with aggressive breast cancer. It is developed based on Listeria technology platform. It was also under development for the treatment of HER2 expressing cancers such as metastatic breast cancer, esophageal cancer and gastric cancer.
OS Therapies overview
OS Therapies is a therapeutics company focused on the identification, development, and commercialization of treatments for Osteosarcoma. The company is headquartered in Fairfax, Virginia, the US
For a complete picture of ADXSHER-2’s drug-specific PTSR and LoA scores, buy the report here.